Autonomous Medication Management (GAM): New perspectives on well-being, quality of life and psychiatric medication;Gestão Autônoma da Medicação (GAM): Novas perspectivas sobre bem-estar, qualidade de vida e medicação psiquiátrica

Ciencia e Saude Coletiva

Volumn 18, Issue 10, 2013, Pages 2879-2887

  del Barrio, Lourdes Rodriguez ^a   Cyr, Céline ^a   Benisty, Lisa ^a   Richard, Pierrette ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Communitybased practices; Empowerment; GAM; Mental health; Psychiatric medication; Qualitative research

Indexed keywords

PSYCHOTROPIC AGENT;

ARTICLE; HUMAN; MEDICATION COMPLIANCE; MENTAL DISEASE; PATIENT SATISFACTION; PERSONAL AUTONOMY; QUALITY OF LIFE; SELF CARE;

HUMANS; MEDICATION ADHERENCE; MENTAL DISORDERS; PATIENT SATISFACTION; PERSONAL AUTONOMY; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; SELF CARE;

EID: 84884579384     PISSN: 14138123     EISSN: 16784561     Source Type: Journal    
DOI: 10.1590/S1413-81232013001000012     Document Type: Article

References (21)

1. Fowler D, Garety P, Kuipers E. Therapie cognitive behaviorale des psychoses. Santé mentale au Québec 1999; 24 (1): 61-88.
2. Liberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Clinical antipsychotic trials of intervention effectiveness investigators: Effectiveness of antipsychotic drugs in patients with schizophrenia. N Engl J Med 2005; 353 (12): 1209-1223.
3. Corrigan PW, Reinke RR, Landsberger SA, Charata A, Toombs GA. The Effects of Atypical Antipsychotic Medications on Psychosocial Outcomes. Schizophr Res 2003; 63 (2): 97-101.
4. Weiden PJ, Dixon L, Frances A, Appelbaum P, Haas G, Rapkin B. Neuroleptic Noncompliance in Schizophrenia. In: Tamminga CA, Schulz SC, editors. Advances in Neuropsychiatry and Psychopharmacology. Schizophrenia Research. New York: Raven Press; 1991. p. 285-296.
5. Commission de l'éthique, de la science et de la technologie (CEST). Médicaments psychotropes et usages élargis: un regard éthique. Québec: CEST; 2009.
6. Rodriguez L, Corin E, Poirel M-L. Le point de vue des utilisateurs sur l'emploi de la médication en psychiatrie: une voix ignorée. Revue québécoise de psychologie 2001; 22 (2): 201-223.
7. Rodriguez L, Corin E, Guay L. La thérapie alternative: se (re) mettre en mouvement. In Lecompte Y, Gagné J. Les ressources alternatives de traitement. Québec: Santé Mentale au Québec, RRASMQ; 2000. p. 49-94.
8. Roe D, Goldblatt H, Baloush-Klienman V, Swarbrick M, Davidson L. Why and how people decide to stop taking prescribed psychiatric medication: Exploring the subjective process of choice. Psychiatr Rehabil J 2009; 33 (1): 38-46.
9. Britten N, Riley R, Morgan M. Resisting psychotropic medicines: a synthesis of qualitative studies of medicine-taking. Advances in psychiatric treatment 2010; 16: 207-218.
10. Rogers A, Day JC, Williams B, Randall F, Wood P, Healy D, Bentall RP. The meaning and management of neuroleptic medication: a study of patients with a diagnosis of schizophrenia. Soc Sci Med 1998; 47 (9): 1313-1323.
11. Yamin S, Vaddadi K. Are we using excessive neuroleptics? An argument for systematic neuroleptic dose reduction in stable patients with schizophrenia with specific reference to clozapine. Int Rev Psychiatry 2010; 22 (2): 138-147.
12. Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker W. Attitudes towards antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002; 63 (1): 49-53
13. Drake RE, Deegan PE, Rapp C. The Promise of Shared Decision Making in Mental Health. Psychiatr Rehabil J 2010; 34 (1): 7-13.
14. Duncan E, Best C, Hagen S. Shared decision making interventions for people with mental health conditions. Cochrane Database Syst Rev 2010; (1): CD007297.
15. Matthias MS, Salyers MP, Rollins AL, Frankel RM. Decision Making in Recovery-Oriented Mental Health Care. Psychiatr Rehabil J 2012; 35 (4): 305-314.
16. Health and Welfare Commissioner. Appraisal Report of the Performance of the Health and Social Services System. Quebec: Health and Welfare Commissioner; 2012.
17. Regroupement des ressources alternatives en santé mentale du Québec, Association des groupes d'intervention en défense des droits en santé mentale du Québec. Taking Back Control; My Self-management Guide to Psychiatric Medication. Québec: Regroupement des ressources alternativesen santé mentale du Québec; 2003.
18. Rodriguez L, Perron N, Ouellette JN. Psychotropes: réguler ou écouter la souffrance. In: Blais L, editeur. Vivre à la marge: réflexions autour de la souffrance sociale. Québec: Les Presses de l'Université Laval; 2008. p. 121-148.
19. Deegan PE, Drake RE. Shared decision making and medication management in the recovery process. Psychiatr Serv 2006; 57 (11): 1636-1639.
20. Aldridge MA. Addressing non-adherence to antipsychotic medication: a harm-reduction approach. J Psychiatr Ment Health Nurs 2012; 19 (1): 85-96.
21. nd Edition. New York: Icarus Project, Freedom Center; 2012.